Hengrui Medicine licenses HRS-1596 to Novo Nordisk
Hengrui Medicine has granted Novo Nordisk exclusive rights to develop, produce, and commercialize the experimental drug HRS-1596 outside of Greater China. The licensing deal is valued at up to $2.6 billion, including an initial payment and milestone-based fees. This agreement marks a significant expansion of Novo Nordisk's pipeline in the weight-loss medication sector.
economy1 h ago
.svg?width=320){kind=logo}
